Medicure (MPH) Price & Analysis

Compare

7 Followers

MPH Stock Chart & Stats

C$1.25

C$0.01(1.22%)

At close: Jan 07 4:00 PM EST

C$1.25

C$0.01(1.22%)

Day’s Range― - ―

52-Week RangeC$0.63 - C$1.43

Previous CloseN/A

Volume1.00K

Average Volume (3M)1.72K

Market Cap

C$12.11M

Enterprise ValueC$8.99M

Total Cash (Recent Filing)C$4.12M

Total Debt (Recent Filing)C$1.00M

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Apr 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding10,436,313

10 Day Avg. Volume717

30 Day Avg. Volume1,717

Financial Highlights & Ratios

PEG Ratio-0.83

Price to Book (P/B)0.44

Price to Sales (P/S)0.42

P/FCF Ratio14.39

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth TrajectorySustained TTM revenue growth (~13% to ~$26.2M) signals improving market traction for core products and deeper hospital uptake. Over a 2–6 month horizon this trend supports scaling fixed-cost absorption, funding incremental R&D, and strengthening commercial leverage.

Conservative Capital StructureVery low leverage (debt-to-equity ~0.06) and a solid equity base provide durable financial flexibility. This conservatism reduces refinancing risk, enables strategic spending or partnerships during loss-making periods, and preserves optionality over the medium term.

Positive Cash GenerationPositive operating (~$1.7M) and free cash flow (~$1.3M), with FCF up ~38%, indicate the business can generate internal funding despite net losses. Cash generation is a durable buffer for working capital and selective investment, lowering near-term dilution risk.

Bears Say

Ongoing Net LossesA persistent TTM net margin around -13.1% reflects ongoing unprofitability. Over months this erodes retained earnings, limits reinvestment capacity, and increases the probability management must seek external capital, which can dilute shareholders or constrain strategy.

Gross Margin CompressionSharp gross margin decline from ~59.7% to ~47.7% materially reduces profit potential and resilience to cost pressures. If structural (mix, pricing, or cost increases), this undermines the pathway to sustainable operating profits despite revenue growth, pressuring long-term margins.

Negative Returns & Limited LeverageA TTM ROE of ~-17.9% shows capital is not generating positive shareholder returns. Coupled with low EBITDA margin (~5.3%), this indicates limited operating leverage: revenue gains may not translate into meaningful profitability without structural margin improvements or cost discipline.

Medicure News

Medicure Sees Revenue Growth Amidst Challenges in Q3 2025

Medicure ( ($TSE:MPH) ) has issued an announcement. Medicure reported a significant increase in total net revenue for...

3M ago

Medicure Inc. to Announce Q3 2025 Financial Results

Medicure ( ($TSE:MPH) ) has shared an announcement. Medicure Inc. announced it will present its financial results for...

3M ago

Medicure Inc’s Pioneering Study on PNPO Deficiency Treatment: A Market Game-Changer?

Medicure Inc (($TSE:MPH)) announced an update on their ongoing clinical study. Study Overview: Medicure Inc (TSE:MPH) is conducting...

3M ago

MPH

Medicure Inc. Reports Increased Revenue and Improved EBITDA for Q2 2025

An update from Medicure ( ($TSE:MPH) ) is now available. Medicure Inc. reported financial results for the quarter...

6M ago

Medicure Inc. to Announce Q2 2025 Financial Results

The latest announcement is out from Medicure ( ($TSE:MPH) ). Medicure Inc. announced it will present its financial...

6M ago

Medicure Inc.’s Pioneering Study on PNPO Deficiency Treatment: A Market Game-Changer?

Medicure Inc (($TSE:MPH)) announced an update on their ongoing clinical study. Study Overview: Medicure Inc. is conducting a...

6M ago

MPH

Medicure Completes Acquisition of West Olympia Pharmacy

Medicure ( ($TSE:MPH) ) has issued an update. Medicure Inc. has completed the acquisition of West Olympia Pharmacy,...

8M ago

Medicure Inc. Reports Q1 2025 Financial Results

Medicure ( ($TSE:MPH) ) just unveiled an announcement. On May 21, 2025, Medicure Inc. released its unaudited financial...

9M ago

Medicure Inc. Earnings Call: Growth Amid Challenges

Medicure Inc (($TSE:MPH)) has held its Q4 earnings call. Read on for the main highlights of the call....

9M ago

Medicure Inc. Reports 2024 Financial Results with Increased Revenue but Net Loss

Medicure ( ($TSE:MPH) ) has issued an update. Medicure Inc. reported its financial results for the year ended...

10M ago

MPH FAQ

What was Medicure Inc’s price range in the past 12 months?

Medicure Inc lowest stock price was C$0.63 and its highest was C$1.43 in the past 12 months.

What is Medicure Inc’s market cap?

Medicure Inc’s market cap is C$12.11M.

When is Medicure Inc’s upcoming earnings report date?

Medicure Inc’s upcoming earnings report date is Apr 22, 2026 which is in 76 days.

How were Medicure Inc’s earnings last quarter?

Medicure Inc released its earnings results on Nov 19, 2025. The company reported -C$0.134 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.134.

Is Medicure Inc overvalued?

According to Wall Street analysts Medicure Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicure Inc pay dividends?

Medicure Inc does not currently pay dividends.

What is Medicure Inc’s EPS estimate?

Medicure Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicure Inc have?

Medicure Inc has 10,436,313 shares outstanding.

What happened to Medicure Inc’s price movement after its last earnings report?

Medicure Inc reported an EPS of -C$0.134 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Medicure Inc?

Currently, no hedge funds are holding shares in TSE:MPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicure Inc

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.